FRANKFURT, March 20 (Reuters) - Swiss drugmaker Novartis on Friday agreed to buy a breast cancer drug candidate for up to $3 billion from U.S. biotech firm Synnovation Therapeutics, adding a targeted ...
Swiss pharmaceutical giant Novartis is set to purchase an experimental breast cancer drug, SNV4818, from US biotech firm Synnovation Therapeutics in a deal worth up to $3 billion.
Novartis (NOVN) announces acquisition of experimental breast cancer drug SNV4818 for up to $3B. Stock dipped 0.94% on the news. Deal closes H1 2026.
WILMINGTON, Del.--(BUSINESS WIRE)--Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated ...
WILMINGTON, Del.--(BUSINESS WIRE)--Synnovation Therapeutics, a precision medicine company focused on the discovery and development of best-in-class targeted medicines, today announced the appointment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results